Healthier You

Via Christi Health


Pediatric Obesity Care Path

(Ages 3-17)

Screening and Diagnosis

- Determine BMI-for-age percentile (Per EMR growth charts or cdc.gov/growthcharts/clinical_charts.htm) ٠
- <85th percentile NOT OVERWEIGHT •
- 85th—94th percentile OVERWEIGHT
- >95th percentile OBESE
- (For infants and children under 2 years, overweight is determined as weight-for-length greater than the 95th percentile, not by BMI)

Treatment



- As appropriate, refer to patient to programs such as Shapedown, and specialists such as a dietitian
- Commit to tracking and reporting processes
- Schedule follow-up appointments

lease note: The Via Christi Health Alliance in Accountable Care, Inc. (the "ACO") in consultation with its affiliated ACO providers developed these care pathways and guidelines based on the most recent evidenced based medicine data. The ACO is continually researching and updating its care pathways and guidelines to reflect the most recent evidence based standards. This information is intended to provide health professionals with information to improve the quality of care and ultimately lower the cost of such care to the patients they serve. By providing this evidence based information, it is not the intention of the ACO to provide specific medical advice for particular patients. Rather we urge each provider to review this material when consulting and evaluating the treatment options suitable for their patients. The ACO affiliated providers are solely responsible for confirming the accuracy, timeliness, completeness, appropriateness and helpfulness of this material and making all medical, diagnostic or prescription decisions.

Weight-related risks & concerns

Even if BMI for age is below the 85th percentile, the patient may be at risk for overweight/obesity and require further evaluation if they have any of the following:

- Parental obesity. This • increases risk of overweight children by 2- or 3-fold.
- Family history of type 2 diabetes, heart disease before age 55 in father or 65 in mother, high blood pressure, high cholesterol, or eating disorders.
- High blood pressure. • Measure at every well-child visit or least once annually. Refer to NIH chart to measure percentiles, then see (h) below for guidelines.
- Patient or family concern • about the patient's weight.
- Medical signs and ٠ symptoms: short stature/developmental delay, acanthosis nigricans, hepatomegaly/right upperquadrant pain, symptoms of sleep apnea.



Via Christi Health

(a) Possible underlying causes or conditions					(b) Medications that may contribute to weight gain	
	Whom to test		Tests/referrals		 High-dose, chronic glucocorticoid treatment Progestins (e.g. depo medroxyprogesterone acetate, norethindrone) Valproate Tricyclic antidepressants (e.g. imipramine, amitriptyline) Cyproheptadine Trazodone Atypical neuroleptics, e.g., olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole 	
	Short stature, goiter, history of decelerated linear growth, or Cushingoid appearance		 TSH 24-hour urine cortisol OR late-night salivary cortisol 			
ader-Willi, dysmorphic features (rdetBiedl, stature, big tongue, la						
	(c) Weight Maint	tena	ance or W	eight-loss T	arge	ets
		OVERWEIGHT (85-95%ile)			OBESE (>95%ile)	
No s	No secondary complications		MAINTENANCE*			MAINTENANCE*
Se	econdary complications	MAINTI		ENANCE*		LOSS [no more than 1 pound (0.5kg) per month]
No	No secondary complications		MAINTENANCE*			LOSS [2-4 pounds (1-2kg) per month]
Se	Secondary complications		LOSS [2-4 pounds (1-2kg) pe month]		er	LOSS [up to 1-2 pounds (0.5kg) per week]
ecreas	e BMI with increasing height					L
	(d) Secondary o	om	plications	s or comorbi	ditie	es
	Whom to test				s/referrals	
• Overweight or obese			HDL cho		total cholesterol, HDL (to calculate non- lesterol; if >145, fasting lipid	
on	-		 Over 95th%ile for gender, age, and height; confirmed at 3 consecutive visits 			
mia	 Age 10 (or onset of puberty) AND Family ethnic history OR signs of insulin resistance (acanthosis nigricans, PCOS, etc.) 		 Random plasma glucose; if >140, follow with fasting plasma glucose (FPG) within 1-2 days OR HbA1c If FPG is 100-120, repeat 			
Sleep apnea, airway obstruction Bleep apnea, • Sleep disturbances • Snoring • Daytime somnolence			Fully polysomnog		/som	nogram in certified sleep lab
Orthopedic problems • Hip, knee, or foot pain • Flat feet • Limited range of motion • Lower-leg bowing						/e, refer to orthopedic specialist apy
Depression/anxiety • Everyone				Child/adolescent Mental health specialist		
syndrome (PCOS) • Abnormal pe		ds • DHEAS		total testosterone		
	ne nn, No s So No ecrease nia on s ecrease sa, ic s s nia on	Whom to test Me Short stature, goiter, history of decelerated linear growth or Cushingoid appearance Developmental delay, dysmorphic features (short stature, big tongue, large head, facial dysmorphia), infantile obesity, hypogonadism. (c) Weight Main No secondary complications Secondary complications <	Whom to test No Short stature, goiter, history of decelerated linear growth, or Cushingoid appearance Developmental delay, dysmorphic features (short stature, big tongue, large head, facial dysmorphia), infantile obesity, hypogonadism. (c) Weight Maintena No secondary complications Secondary complications Secondary complications Secondary complications Secondary complications Image: Secondary complications Secondary complications Image: Secondary complications Secondary complications Image: Secondary complication	Whom to test Tests/reference Short stature, goiter, history of decelerated linear growth, or Cushingoid appearance • TSH • 24-hour cortisol of salivary Developmental delay, dysmorphic features (short stature, big tongue, large head, facial dysmorphia), infantile obesity, hypogonadism. • Refer for testing, C) Weight Maintenance or W OVER (85 No secondary complications MAINT Secondary complications ICOSS [2-4 p m ecrease BMI with increasing height ICOSS [2-4 p m (d) Secondary complications MAINT No secondary complications ICOSS [2-4 p m on • Overweight or obese on • Overweight or obese on • Overweight or obese on • Everyone • Age 10 (or onset of puberty) AND AND • Enlarged liver • Enlarged liver • Sleep disturbances	Whom to test Tests/referrals ae Short stature, goiter, history of decelerated linear growth, or Cushingoid appearance • TSH • 24-hour urine cortisol OR late-night salivary cortisol Developmental delay, dysmorphic features (short stature, big tongue, large head, facial dysmorphia), infantile obesity, hypogonadism. • Refer for genetic testing, counseling (c) Weight Maintenance or Weight-loss T OVERWEIGHT (85-95%ile) No secondary complications MAINTENANCE* Secondary complications MAINTENANCE* No secondary complications MAINTENANCE* Secondary complications MAINTENANCE* No secondary complications MAINTENANCE* Secondary complications MAINTENANCE* Image: Condary complications MAINTENANCE* VOVerweight or obese • Random HDL chol on • Everyone • Overweight or obese • Age 10 (or onset of puberty) AND • Random fasting pl OR • Family ethnic history OR signs of insulin resistance (acanthosis nigricans, PCOS, etc.) • HbA1c • Flat feet • Fully poly • Steep disturbances • Fully poly • Flat feet • Physical • Steep disturbances	Whom to test Tests/referrals a Short stature, goiter, history of decelerated linear growth, or Cushingoid appearance • TSH • 24-hour urine cortisol OR late-night salivary cortisol Developmental delay, dysmorphic features (short stature, big tongue, large head, facial dysmorphia), infantile obesity, hypogonadism. • Refer for genetic testing, counseling (C) Weight Maintenance or Weight-loss Target OVERWEIGHT (85-95%ile) No secondary complications MAINTENANCE* Secondary complications MAINTENANCE* No secondary complications MAINTENANCE* Secondary complications MAINTENANCE* Secondary complications MAINTENANCE* Overweight or obese • Random total HDL choleste on • Everyone • Over weight or obese • Age 10 (or onset of puberty) AND • Random total HDL choleste • Age 10 (or onset of puberty) AND • Random plass fasting plasm fasting pl

Please note: The Via Christi Health Alliance in Accountable Care, Inc. (the "ACO") in consultation with its affiliated ACO providers developed these care pathways and guidelines based on the most recent evidence based medicine data. The ACO is continually researching and updating its care pathways and guidelines to reflect the most recent evidence based standards. This information is intended to provide health professionals with information to improve the quality of care and ultimately lower the cost of such care to the patients they serve. By providing this evidence based information, it is not the intention of the ACO to provide specific medical advice for particular patients. Rather we urge each provider to review this material when consulting and evaluating the treatment options suitable for their patients. The ACO affiliated providers are solely responsible for confirming the accuracy, timeliness, completeness, appropriateness and helpfulness of this material and making all medical, diagnostic or prescription decisions.